Prasugrel

證據等級: L5

預測適應症: 10 個

Prasugrel: From Antiplatelet Therapy (ACS/PCI) to Pulmonary Hypertension

One-Sentence Summary

Prasugrel is a thienopyridine-class P2Y12 receptor antagonist established as antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention (per the literature context in this evidence pack). The TxGNN model predicts it may be effective for Pulmonary Hypertension, but currently only 2 clinical trials and 2 publications are on file, and none directly test prasugrel in this indication — the signal remains at the mechanistic-hypothesis stage.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no Finland licenses on file); literature context points to antiplatelet use in ACS/PCI
Predicted New Indication	Pulmonary Hypertension
TxGNN Prediction Score	99.88%
Evidence Level	L4
Finland Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for prasugrel. Based on known information within this evidence pack, prasugrel is a thienopyridine-class P2Y12 receptor antagonist (antiplatelet drug) in the same family as clopidogrel; its efficacy in acute coronary syndrome/PCI settings is well established in the literature, and mechanistically this class may be applicable to other vascular/thrombotic conditions.

The proposed link to pulmonary hypertension rests on a single hypothesis: in chronic thromboembolic pulmonary hypertension (CTEPH), a subtype of pulmonary hypertension, anticoagulant therapy is standard adjunctive care, so an antiplatelet agent might plausibly play an analogous thrombo-preventive role. However, this is a class-level, indirect inference — no direct evidence currently supports prasugrel's use for pulmonary hypertension itself.

Both retrieved clinical trials were graded relevance C (low relevance) by the evidence review: one is an observational NOAC-management study in elderly atrial fibrillation patients, the other a retrospective eligibility analysis for cancer-associated thrombosis. Neither involves prasugrel or pulmonary hypertension directly. Similarly, the two literature items provide only background context (a COVID-19 comorbidity registry, and a clopidogrel/prasugrel adherence study in ACS/PCI patients) rather than direct evidence for this indication. This is why the evidence level is capped at L4 (mechanism-level reasoning only) despite the high TxGNN score.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03993119	N/A	Completed	500	Observational cross-sectional study of NOAC management in elderly non-valvular AF patients in Spain; no direct link to prasugrel or pulmonary hypertension (relevance grade C — background noise)
NCT04846556	N/A	Completed	300	Retrospective study on eligibility for the CARAVAGGIO cancer-associated thrombosis trial; no direct link to prasugrel or pulmonary hypertension (relevance grade C — background noise)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21241206	2011	Cohort	Current Medical Research and Opinion	Evaluates factors associated with clopidogrel/prasugrel use and adherence after PCI in ACS patients — confirms prasugrel's established antiplatelet role in ACS, but not related to pulmonary hypertension
34713782	2021	Cohort/Observational	Kardiologiia	ACTIV SARS-CoV-2 registry analysis of background comorbidity therapy on COVID-19 outcomes; not specific to prasugrel or pulmonary hypertension

Finland Market Information

Prasugrel currently has no marketing authorizations on file in Finland (0 authorizations; market status: not marketed).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The only available evidence — two clinical trials (both graded low relevance) and two publications (neither addressing prasugrel in pulmonary hypertension) — does not support a direct or even strong indirect signal. The proposed mechanism (antiplatelet effect analogous to anticoagulation in CTEPH) is plausible but unverified, and core drug data (MOA, package insert warnings/contraindications) are also missing.

To proceed, the following is needed:

TFDA/Fimea package insert data (blocking gap: warnings/contraindications, DG001)
DrugBank mechanism of action data (DG002)
Preclinical or mechanistic studies evaluating P2Y12 inhibition specifically in pulmonary vascular remodeling or CTEPH
Dedicated clinical trials or case series testing prasugrel in pulmonary hypertension populations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.